Logo image of NKTR

NEKTAR THERAPEUTICS (NKTR) Stock Price, Quote, News and Overview

NASDAQ:NKTR - Nasdaq - US6402681083 - Common Stock - Currency: USD

23.65  -1.35 (-5.4%)

After market: 23.94 +0.29 (+1.23%)

NKTR Quote, Performance and Key Statistics

NEKTAR THERAPEUTICS

NASDAQ:NKTR (7/28/2025, 8:00:02 PM)

After market: 23.94 +0.29 (+1.23%)

23.65

-1.35 (-5.4%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High37.38
52 Week Low6.45
Market Cap394.01M
Shares16.66M
Float16.50M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-06 2025-08-06/amc
IPO05-03 1994-05-03


NKTR short term performance overview.The bars show the price performance of NKTR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60 80 100

NKTR long term performance overview.The bars show the price performance of NKTR in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 50 -50 100 150

The current stock price of NKTR is 23.65 USD. In the past month the price decreased by -8.19%. In the past year, price increased by 31.39%.

NEKTAR THERAPEUTICS / NKTR Daily stock chart

NKTR Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 58.73 765.88B
JNJ JOHNSON & JOHNSON 16.62 399.94B
NVO NOVO-NORDISK A/S-SPONS ADR 18.7 306.59B
NVS NOVARTIS AG-SPONSORED ADR 13.13 224.91B
AZN ASTRAZENECA PLC-SPONS ADR 16.51 222.71B
MRK MERCK & CO. INC. 10.79 211.08B
PFE PFIZER INC 7.57 138.21B
SNY SANOFI-ADR 10.83 120.44B
BMY BRISTOL-MYERS SQUIBB CO 6.47 96.69B
GSK GSK PLC-SPON ADR 8.43 75.65B
ZTS ZOETIS INC 25.04 67.12B
TAK TAKEDA PHARMACEUTIC-SP ADR 62.22 45.19B

About NKTR

Company Profile

NKTR logo image Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. The company is headquartered in San Francisco, California and currently employs 61 full-time employees. The company is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. The company is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Company Info

NEKTAR THERAPEUTICS

455 Mission Bay Boulevard South

San Francisco CALIFORNIA 94158 US

CEO: Howard W. Robin

Employees: 61

NKTR Company Website

NKTR Investor Relations

Phone: 18554826587

NEKTAR THERAPEUTICS / NKTR FAQ

What is the stock price of NEKTAR THERAPEUTICS today?

The current stock price of NKTR is 23.65 USD. The price decreased by -5.4% in the last trading session.


What is the ticker symbol for NEKTAR THERAPEUTICS stock?

The exchange symbol of NEKTAR THERAPEUTICS is NKTR and it is listed on the Nasdaq exchange.


On which exchange is NKTR stock listed?

NKTR stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for NEKTAR THERAPEUTICS stock?

14 analysts have analysed NKTR and the average price target is 96.73 USD. This implies a price increase of 309.01% is expected in the next year compared to the current price of 23.65. Check the NEKTAR THERAPEUTICS stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is NEKTAR THERAPEUTICS worth?

NEKTAR THERAPEUTICS (NKTR) has a market capitalization of 394.01M USD. This makes NKTR a Small Cap stock.


How many employees does NEKTAR THERAPEUTICS have?

NEKTAR THERAPEUTICS (NKTR) currently has 61 employees.


What are the support and resistance levels for NEKTAR THERAPEUTICS (NKTR) stock?

NEKTAR THERAPEUTICS (NKTR) has a support level at 23.64 and a resistance level at 25.16. Check the full technical report for a detailed analysis of NKTR support and resistance levels.


Is NEKTAR THERAPEUTICS (NKTR) expected to grow?

The Revenue of NEKTAR THERAPEUTICS (NKTR) is expected to decline by -56.51% in the next year. Check the estimates tab for more information on the NKTR EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy NEKTAR THERAPEUTICS (NKTR) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does NEKTAR THERAPEUTICS (NKTR) stock pay dividends?

NKTR does not pay a dividend.


When does NEKTAR THERAPEUTICS (NKTR) report earnings?

NEKTAR THERAPEUTICS (NKTR) will report earnings on 2025-08-06, after the market close.


What is the Price/Earnings (PE) ratio of NEKTAR THERAPEUTICS (NKTR)?

NEKTAR THERAPEUTICS (NKTR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-12.45).


NKTR Technical Analysis

ChartMill assigns a technical rating of 8 / 10 to NKTR. When comparing the yearly performance of all stocks, NKTR is one of the better performing stocks in the market, outperforming 94.32% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

NKTR Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to NKTR. No worries on liquidiy or solvency for NKTR as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NKTR Financial Highlights

Over the last trailing twelve months NKTR reported a non-GAAP Earnings per Share(EPS) of -12.45. The EPS increased by 9.78% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -51.92%
ROE -968.42%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-26.32%
Sales Q2Q%-51.73%
EPS 1Y (TTM)9.78%
Revenue 1Y (TTM)-3.19%

NKTR Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 81% to NKTR. The Buy consensus is the average rating of analysts ratings from 14 analysts.

For the next year, analysts expect an EPS growth of -2.04% and a revenue growth -56.51% for NKTR


Ownership
Inst Owners66.83%
Ins Owners1.29%
Short Float %N/A
Short Ratio0.4
Analysts
Analysts81.43
Price Target96.73 (309.01%)
EPS Next Y-2.04%
Revenue Next Year-56.51%